Trial Search Results

Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer

The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Device: Stereotactic Radiosurgery (Cyberknife)


Phase 2


Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.

   - Histologically confirmed malignancies of the pancreas, (ampulla of Vater or
   periampullary duodenum, tumors may be included when the head of pancreas is
   secondarily involved and unresectable criteria are met).

   - Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy.
   CT criteria for unresectability include encasement of the superior mesenteric vein
   (SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery

   - Patients with metastatic disease may be treated if they are symptomatic from the
   primary tumor.

   - Eastern Clinical Oncology Group performance status 0, 1 or 2.

Exclusion Criteria:Chemotherapy within 1 month of registration.

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Stanford Cancer Clinical Trials Office
Not Recruiting